- IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
- IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
- IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
- IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
- Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
- IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
- IGC Pharma Reports Third Quarter Fiscal 2024 Results
- IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
- IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
- IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial
More ▼
Key statistics
On Thursday, IGC Pharma Inc (IGC:ASQ) closed at 0.40, -19.98% below its 52-week high of 0.4999, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.407 |
---|---|
High | 0.4149 |
Low | 0.3912 |
Bid | 0.408 |
Offer | 0.4099 |
Previous close | 0.4065 |
Average volume | 898.59k |
---|---|
Shares outstanding | 66.06m |
Free float | 52.46m |
P/E (TTM) | -- |
Market cap | 26.43m USD |
EPS (TTM) | -0.2479 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.
More ▼